Embryonic signaling in melanoma: Potential for diagnosis and therapy

Laboratory Investigation

Volumn 91, Issue 6, 2011, Pages 819-824

  Strizzi, Luigi ^a   Hardy, Katharine M ^a   Kirsammer, Gina T ^a   Gerami, Pedram ^a   Hendrix, Mary J C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

biomarker; melanoma; Nodal; plasticity; therapeutic target

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; GSK 0941; GSK 1120212; MORPHOGEN; NOTCH RECEPTOR; PROTEIN NODAL; SELUMETINIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VEMURAFENIB; XL 147;

ARTICLE; CANCER SURVIVAL; EMBRYONAL TISSUE; GENE MUTATION; HUMAN; MELANOMA; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION; STEM CELL; TUMOR CELL;

CELL LINE, TUMOR; EMBRYO, MAMMALIAN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MODELS, BIOLOGICAL; NODAL PROTEIN; PHENOTYPE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 79957624574     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.63     Document Type: Article

References (37)

1. Seykora J, Elder D. Dysplastic nevi and other risk markers for melanoma. Semin Oncol 1996;23:682-687. (Pubitemid 26424692)
2. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147. (Pubitemid 41653105)
3. Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 2010;19:1557-1568.
4. El Ghissassi F, Baan R, Straif K, et al. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-part D: radiation. Lancet Oncol 2009;10:751-752.
5. Lodha S, Saggar S, Celebi JT, et al. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting. J Cut Pathol 2008;35:349-352. (Pubitemid 351363772)
6. Kashani-Sabet M, Rangel J, Torabian S, et al. A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA 2009;106:6268-6272.
7. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009;33:1146-1156.
8. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
9. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185-193. (Pubitemid 40945448)
10. Hendrix MJ, Seftor EA, Seftor RE, et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nature Rev Cancer 2007;7:246-255. (Pubitemid 46480969)
11. Hendrix MJ, Seftor EA, Hess AR, et al. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Rev Cancer 2003;3:411-421. (Pubitemid 37328845)
12. Dome B, Hendrix MJ, Paku S, et al. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 2007;170:1-15. (Pubitemid 47339184)
13. Ruf W, Seftor EA, Petrovan RJ, et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003;63:5381-5389. (Pubitemid 37139855)
14. Hendrix MJ, Seftor RE, Seftor EA, et al. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res 2002;62:665-668. (Pubitemid 34126938)
15. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010;23:746-759.
16. Quintana E, Shackleton M, Foster HR, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010;18:510-523.
17. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010;141:583-594.
18. Kyrgidis A, Tzellos TG, Triaridis S. Melanoma: stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinog 2010;9:3.
19. Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Transl Med 2009;7:86.
20. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer 2011;104:392-398.
21. Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol 2010;22:178-183.
22. Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68:4853-4861.
23. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-972.
24. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to BRAF( V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-977.
25. Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600Emutated melanomas. Mol Cancer Ther 2008;7:2876-2883.
26. Gopal YN, Deng W, Woodman SE, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY- 142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010;70:8736-8747.
27. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAFtargeted melanoma cells. Cancer Res 2010;70:6670-6681.
28. Smalley KS, Haas NK, Brafford PA, et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-1144. (Pubitemid 43881305)
29. Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment Cell Res 2007;20:458-465. (Pubitemid 47568831)
30. Hardy KM, Kirschmann DA, Seftor EA, et al. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 2010;70:10340-10350.
31. Postovit LM, Margaryan NV, Seftor EA, et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA 2008;105:4329-4334. (Pubitemid 351754380)
32. Strizzi L, Hardy KM, Seftor EA, et al. Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Res 2009;69:7131-7134.
33. Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 2006;12:925-932. (Pubitemid 44175144)
34. Yu L, Harms PW, Pouryazdanparast P, et al. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions. Mod Pathol 2010;23:1209-1214.
35. Costa FF, Seftor EA, Bischof JM, et al. Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics 2009;1:387-398.
36. Strizzi L, Postovit LM, Margaryan NV, et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol 2009;4:67-78.
37. Ascierto PA, Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. J Transl Med 2010;8:38.